Roth Capital assumed coverage on shares of Myomo (NYSEAMERICAN:MYO) in a research report report published on Friday, March 9th. The brokerage issued a buy rating and a $9.00 price objective on the stock.
Separately, HC Wainwright set a $12.00 price target on Myomo and gave the stock a buy rating in a research report on Thursday, March 8th.
NYSEAMERICAN MYO traded down $0.09 during trading hours on Friday, reaching $2.97. 321,600 shares of the company’s stock were exchanged, compared to its average volume of 803,048. Myomo has a one year low of $2.07 and a one year high of $23.20.
Institutional investors have recently modified their holdings of the stock. Hudson Bay Capital Management LP acquired a new stake in Myomo during the 4th quarter worth $294,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Myomo in the 4th quarter valued at about $257,000. Finally, Virtu Financial LLC acquired a new stake in shares of Myomo in the 4th quarter valued at about $124,000.
WARNING: “Roth Capital Begins Coverage on Myomo (NYSEAMERICAN:MYO)” was posted by Enterprise Leader and is the property of of Enterprise Leader. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://theenterpriseleader.com/2018/04/02/myomo-nyseamericanmyo-now-covered-by-analysts-at-roth-capital.html.
Myomo Company Profile
Myomo, Inc is a United States-based medical device company specializing in myoelectric orthotics for people with neurological disorders. The Company’s products help to restore function in individuals with neuromuscular conditions, such as brachial plexus injury, spinal cord injury, multiple sclerosis and stroke.
Receive News & Ratings for Myomo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myomo and related companies with MarketBeat.com's FREE daily email newsletter.